Truist Securities analyst Tobey Sommer reiterated a Buy rating and $40.00 price target on AMN Healthcare (NYSE: AMN)

The analyst comments "Earlier this week, we hosted investor meetings with AMN Healthcare's (AMN, Buy) CEO, CFO and IR in Denver and Minneapolis. Key topics: (1) improving Travel Nurse demand; (2) margin recovery opportunities; (3) the outlook for International Nursing amid embassy bottlenecks; and (4) labor disruption opportunities. Travel Nurse orders are continuing to improve while bill rates are beginning to move higher in pockets. We think the NDR offers further evidence of a cyclical recovery in Travel Nurse and reinforces our Buy thesis."

For an analyst ratings summary and ratings history on AMN Healthcare click here. For more ratings news on AMN Healthcare click here.

Shares of AMN Healthcare closed at $34.56 yesterday.